Company news

Calidi Biotherapeutics, Inc. news in 2025

Calidi Biotherapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

November 17, 2025

Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights

November 13, 2025

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

November 10, 2025

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

November 4, 2025

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

October 30, 2025

Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine

October 22, 2025

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston

September 29, 2025

Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

August 21, 2025

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

August 20, 2025

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

August 8, 2025

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma

July 29, 2025

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

July 25, 2025

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24

July 22, 2025

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

July 10, 2025

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

July 9, 2025

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

July 8, 2025

Calidi Biotherapeutics Announces Shareholder Letter from CEO

June 27, 2025

Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting

June 2, 2025

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 14, 2025

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

April 28, 2025

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

April 25, 2025

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

April 23, 2025

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

April 22, 2025

Decks in 2025